Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: A marker for potential molecularly targeted treatment?

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 416-422

  Raspollini, M R ^a   Susini, T ^a   Amunni, G ^a   Paglierani, M ^a   Castiglione, F ^a   Garbini, F ^a   Carriero, C ^a   Scarselli, G ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

HER 2 neu; Platinum; Trastuzumab; Uterine carcinosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PLATINUM; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 17; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; EAR RECONSTRUCTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UTERUS CARCINOMA; UTERUS DISEASE; UTERUS SARCOMA;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOSARCOMA; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, ERBB-2; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TISSUE CULTURE TECHNIQUES; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 33645341956     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00410.x     Document Type: Article

References (36)

1. Ali S Wells M. Mixed mullerian tumors of the uterine corpus: a review. Int J Gynecol Cancer 1993 3 1 11.
2. Sreenan JJ Hart WR. Carcinosarcoma of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995 19 666 74.
3. Abeln EC Smit VT Wessels JW de Leeuw WJ Cornelisse CJ Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997 183 424 31.
4. Kounelis S Jones MW Papadaki H Bakker A Swalsky P Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998 29 82 7.
5. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcoma or metaplastic carcinomas? J Clin Pathol 2002 55 321 5.
6. Van Rijswijk REN Tognon G Burger CW Baak JP Kenemans P Vermorken JB. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer 2004 4 52 60.
7. Pautier P Genestie C Fizazi K et al. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int J Gynecol Cancer 2002 12 749 54.
8. Nielsen SN Podratz KC Scheithauer BW O'Brien PC. Clinicopathological analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 1989 34 372 8.
9. Iwasa Y Haga H Konishi I et al. Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients. Cancer 1998 82 512 9.
10. Sartori E Bazzurini L Gadducci A et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CFT study. Gynecol Oncol 1997 67 70 5.
11. Arrastia CD Fluchter RG Clark M et al. Uterine carcinosarcomas: incidence and trend in management and survival. Gynecol Oncol 1997 65 158 63.
12. Olayioye MA Neve RM Lane HA Hynes NE. The ErbB signaling network: receptor heterodimerization in the development and cancer. EMBO J 2000 19 3159 67.
13. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene. Science 1987 235 177 82.
14. Seshadri R Firgaira FA Horsfall DJ McCaul K Setlur V Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993 11 1936 42.
15. Guy CT Webster MA Schaller M Parsons TJ Cardiff RD Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Procl Natl Acad Sci U S A 1992 89 10578 82.
16. Smith G Henderson JC. New treatments for breast cancer. Semin Oncol 1996 23 506 28.
17. Fossati R Confalonieri C Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 1998 16 3439 60.
18. TNM Classification of malignant tumours. UICC. Sobin LH and Wittekind Ch eds. Geneva, Switzerland. 60th edn. 2002.
19. Silverberg SG Kurman RJ. Tumours of the uterine corpus and gestational trophoblastic disease. In Silverberg SG Kurman RJ eds. Atlas of tumor pathology third series, fasc 3. Washington, DC Armed Forces Institute of Pathology 1991 166 77.
20. Lal P Salazar PA Hudis CA Ladanyi M Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. A single-institution experience of 2279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004 121 631 6.
21. Kaplan EL Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 457 81.
22. Winter WE III. Seidmann JD Krivak TC et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003 91 3 8.
23. Emoto M Ishiguro M Iwasaki H Kikuchi M Kawarabayashi T. Effect of angiogenesis inhibitor TNP-470 on the growth, blood flow, and microvessel density in xerografts of human uterine carcinosarcoma in nude mice. Gynecol Oncol 2003 89 88 94.
24. Hetzel DJ Wilson TO Keeney GL Roche PC Cha SS Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992 47 179 85.
25. Nishioka T West CM Gupta N et al. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 1999 125 96 100.
26. Camilleri-Broet S Hardy-Bessard AC Le Tourneau A et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of GINECO group. Ann Oncol 2004 15 104 12.
27. Slamon DJ Leyland-Jones B Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 783 92.
28. Swisher EM Gown AM Skelly M et al. The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996 60 81 8.
29. Ramondetta LM Burke TW Jhingran A et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003 90 529 6.
30. Raspollini MR Susini T Alunni G et al. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 2005 96 159 67.
31. Sawada M Tsuda H Kimura M et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoprotein between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 2003 94 986 91.
32. Costa MJ Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer 1996 77 533 42.
33. Sartori E Bazzurini L Gadducci A et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CFT study. Gynecol Oncol 1997 67 70 5.
34. Iwasa Y Haga H Konishi I et al. Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients. Cancer 1998 82 512 9.
35. Latif Z Watters AD Dunn I Grigor K Underwood MA Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004 40 56 63.
36. Xia W Lau YK Zhang HZ et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of the oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999 5 4164 74.